292 related articles for article (PubMed ID: 19808215)
1. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.
Pergola PE; Gartenberg G; Fu M; Wolfson M; Rao S; Bowers P
Clin J Am Soc Nephrol; 2009 Nov; 4(11):1731-40. PubMed ID: 19808215
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.
Pergola PE; Gartenberg G; Fu M; Sun S; Wolfson M; Bowers P
Clin J Am Soc Nephrol; 2010 Apr; 5(4):598-606. PubMed ID: 20185602
[TBL] [Abstract][Full Text] [Related]
3. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.
Spinowitz B; Germain M; Benz R; Wolfson M; McGowan T; Tang KL; Kamin M;
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1015-21. PubMed ID: 18400964
[TBL] [Abstract][Full Text] [Related]
5. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
6. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients.
Grossman HA; Goon B; Bowers P; Leitz G;
J Acquir Immune Defic Syndr; 2003 Dec; 34(4):368-78. PubMed ID: 14615654
[TBL] [Abstract][Full Text] [Related]
7. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease.
Provenzano R; Singh AK
Endocr Pract; 2007; 13(3):251-9. PubMed ID: 17599856
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.
McGowan T; Vaccaro NM; Beaver JS; Massarella J; Wolfson M
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1006-14. PubMed ID: 18417741
[TBL] [Abstract][Full Text] [Related]
10. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
Henry DH; Gordan LN; Charu V; Wilhelm FE; Williams D; Xie J; Woodman RC
Curr Med Res Opin; 2006 Jul; 22(7):1403-13. PubMed ID: 16834839
[TBL] [Abstract][Full Text] [Related]
11. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
[TBL] [Abstract][Full Text] [Related]
12. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB
J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
[TBL] [Abstract][Full Text] [Related]
13. Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients.
Azmandian J; Abbasi MR; Pourfarziani V; Nasiri AA; Ossareh S; Ezzatzadegan Jahromi S; Sanadgol H; Amini S; Shahvaroughi Farahani A
Am J Nephrol; 2018; 48(4):251-259. PubMed ID: 30253403
[TBL] [Abstract][Full Text] [Related]
14. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
Germain M; Ram CV; Bhaduri S; Tang KL; Klausner M; Curzi M
Nephrol Dial Transplant; 2005 Oct; 20(10):2146-52. PubMed ID: 15985516
[TBL] [Abstract][Full Text] [Related]
15. Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia.
Crémieux PY; Fastenau JM; Kosicki G; Piech CT; Fendrick AM
J Manag Care Pharm; 2004; 10(6):531-7. PubMed ID: 15548125
[TBL] [Abstract][Full Text] [Related]
16. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and treatment of anemia with once-weekly epoetin alfa in patients with diabetes and chronic kidney disease.
Lorber DL; Provenzano R; McClellan W
Endocr Pract; 2006; 12(5):506-13. PubMed ID: 17002925
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
